Bristol Myers (BMY) will spend $40B in the U.S. over the next five years, CEO Christopher Boerner wrote in STAT. Through this investment plan, “we will strengthen our presence across the country, ramp up radiopharmaceutical manufacturing, and invest in artificial intelligence and machine learning to help us significantly increase the pace of innovation,” Boerner said. “It is our commitment to patients that drives each investment we make.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers appoints Cari Gallman as Chief Policy Officer
- Trump to sign order streamlining U.S. drug manufacturing regulations, WaPo says
- Trump urges drugmakers to accept lower prices on prescriptions, Bloomberg says
- Insider Moves: Procter & Gamble, Strategy, Merck, Bristol-Myers, AGNC
- MHRA authorizes under-skin injection version of Bristol Myers’ Opdivo
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue